HPLC-MS/MS method for the simultaneous quantification of dolutegravir, elvitegravir, rilpivirine, darunavir, ritonavir, raltegravir and raltegravir-β-d-glucuronide in human plasma
| العنوان: | HPLC-MS/MS method for the simultaneous quantification of dolutegravir, elvitegravir, rilpivirine, darunavir, ritonavir, raltegravir and raltegravir-β-d-glucuronide in human plasma |
|---|---|
| المؤلفون: | Jean-Marc Tréluyer, Déborah Hirt, Radia Aboura, Gabrielle Lui, Sihem Benaboud, Naïm Bouazza, Frantz Foissac, Sana Boujaafar, Inès Gana, Yi Zheng |
| المساهمون: | Evaluation thérapeutique et pharmacologie périnatale et pédiatrique (EA_7323), Université Paris Descartes - Paris 5 (UPD5), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP) |
| المصدر: | Journal of Pharmaceutical and Biomedical Analysis Journal of Pharmaceutical and Biomedical Analysis, Elsevier, 2020, 182, pp.113119-. ⟨10.1016/j.jpba.2020.113119⟩ |
| بيانات النشر: | HAL CCSD, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Anti-HIV Agents, Clinical Biochemistry, Pharmaceutical Science, Integrase inhibitor, 01 natural sciences, Analytical Chemistry, chemistry.chemical_compound, Tandem Mass Spectrometry, Drug Discovery, medicine, Humans, [CHIM]Chemical Sciences, Chromatography, High Pressure Liquid, Spectroscopy, Darunavir, Randomized Controlled Trials as Topic, Chromatography, medicine.diagnostic_test, 010405 organic chemistry, Chemistry, Elvitegravir, 010401 analytical chemistry, Reproducibility of Results, Raltegravir, 3. Good health, 0104 chemical sciences, Therapeutic drug monitoring, Rilpivirine, Dolutegravir, Ritonavir, Drug Monitoring, medicine.drug |
| الوصف: | Therapeutic drug monitoring (TDM) is essential in the optimization of antiretroviral (ARV) treatments. In this work, we describe a new method for the simultaneous quantification of six molecules: the three novel ARV agents dolutegravir (DTG), elvitegravir (ELV) and rilpivirine (RPV), the first integrase inhibitor raltegravir (RAL) and its major metabolite the raltegravir-β- d -glucuronide (RAL-GLU), an protease inhibitor darunavir (DRV) and its booster ritonavir (RTV) in human plasma. The drugs were extracted from 100 μL of plasma by a simple method of protein precipitation using acetonitrile. The separation was carried out on a Kinetex phehyl-hexyl column using a phase mobile composed of 55 % of water (0.05 % formic acid,v/v) and 45 % of methanol (0.05 % formic acid,v/v). The flow rate was set at 0.5 mL/min. The calibration ranged from 60 to 15000 ng/mL for DRV, from 20 to 5000 ng/mL for DTG and ELV, from 10 to 2500 ng/mL for RAL, RAL-GLU, RTV and RPV. The proposed method was validated with a good precision (inter- and intra-day CV% inferior to 12.3 %) and a good accuracy (inter- and intra-day bias between −9.9 % and 10 %) for all the analytes. The proposed method is simple, reliable and suitable for therapeutic drug monitoring (TDM) and for pharmacokinetics studies. |
| اللغة: | English |
| تدمد: | 0731-7085 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22c6923c424756daf8f2f0a57b32eeb7Test https://hal.archives-ouvertes.fr/hal-03489828Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....22c6923c424756daf8f2f0a57b32eeb7 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 07317085 |
|---|